Aim: In this study, we proposed a peritoneal scintigraphy with a different marker, the 99mTechnetium-Icodextrin, to evaluate the distribution of the dialysate within the peritoneal cavity in peritoneal dialysis (PD) patients. Methods: 99mTc-Icodextrin scintigraphy was performed in 16 PD patients. 0.5 ml of 7.5% Icodextrin solution was labeled with 74 megabecquerel (MBq) of 99mTc and then added to 2,000 ml of dialysate solution (2.5% dextrose). The peritoneum scintigraphy was performed by a SPECT gamma camera with the peritoneal cavity filled and after the complete drainage of the radio compound-dialysate mixture. The images were reviewed for evidence of peritoneal leaks, hernias, loculated fluid collections, and peritoneal membrane adhesions. Results: Abnormal findings were detected by 99mTc-Icodextrin scintigraphy in 4 (25%) out of 16 patients and included retroperitoneal (n = 1), diaphragmatic (n = 1) and inguinal (n = 1) leakages and peritoneal membrane adhesions (n = 1). Conclusions: Peritoneum scintigraphy with 99mTc-Icodextrin is a useful method to detect some complications occurring during peritoneal dialysis; it offers excellent imaging to assess these complications.

Keywords:
Peritoneal dialysis, Scintigraphy, Icodextrin, Peritoneum imaging
1.
Cochran ST, Do HM, Ronaghi A, Nissenson AR, Kadell BM: Complications of peritoneal dialysis: evaluation with CT peritoneography. Radiographics 1997;17:869-878.
2.
Stuart S, Booth TC, Cash CJ, Hameeduddin A, Goode JA, Harvey C, Malhotra A: Complications of continuous ambulatory peritoneal dialysis. Radiographics 2009;29:441-460.
3.
Nissenson AR, Gentile DE, Soderblom RE, Oliver DF, Brax C: Morbidity and mortality of continuous ambulatory peritoneal dialysis: regional experiences and long-term prospects. Am J Kidney Dis 1986;7:229-234.
4.
Twardowski ZJ, Tully RJ, Ersoy FF, Dedhia NM: Computerized tomography with and without intraperitoneal contrast for determination on intraabdominal fluid distribution and diagnosis of complications in peritoneal dialysis patients. ASAIO Trans 1990;36:95-103.
5.
Roub LW, Drayer BP, Orr DP, Oh KS: Computed tomography positive contrast peritoneography. Radiology 1979;131:699-704.
6.
Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE: Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR Am J Roentgenol 1979;133:221-223.
7.
Hollett MD, Marn CS, Ellis JH, Francis IR, Swartz RD: Complications of continuous ambulatory peritoneal dialysis: evaluation with CT peritoneography. AJR Am J Roentgenol 1992;159:983-989.
8.
Dörsam J, Knopp MV, Schad L, Piesche S, Carl S, Oesingmann N: Elimination of gadolinium-DTPA by peritoneal dialysis. Nephrol Dial Transplant 1995;10:1228-1230.
9.
Prokesch RW, Schima W, Schober E, Vychytil A, Fabrizii V, Bader TR: Complications of continuous ambulatory peritoneal dialysis: findings on MR peritoneography. AJR Am J Roentgenol 2000;174:987-991.
10.
Galan A, Cowper SE, Bucala R: Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006;18:614-617.
11.
Cesani F, Zuckermann JA, Patange VB, Briscoe EG: Peritoneoscintigraphy using Tc-99m MAA for diagnosis of diaphragmatic disruptions in trauma patients. Clin Nucl Med 1996;21:290-292.
12.
Rajnish A, Ahmad M, Kumar P: Peritoneal scintigraphy in the diagnosis of complications associated with continuous ambulatory peritoneal dialysis. Clin Nucl Med 2003;28:70-71.
13.
Burton DA, Cashman JN: Allergic reaction to nanocolloid during lymphoscintigraphy for sentinel lymph node biopsy. Br J Anaesth 2003;90:105.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.